Caverject 10 micrograms, Powder and Solvent for Solution for Injection

  • Name:

    Caverject 10 micrograms, Powder and Solvent for Solution for Injection

  • Company:
    info
  • Active Ingredients:

    Alprostadil

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 05/06/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 12/11/2020

Click on this link to Download PDF directly

Pfizer Healthcare Ireland

Pfizer Healthcare Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Accupro 10 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 20 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 40 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 5 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accuretic 20 mg/12.5 mg Tablets Active Ingredients Hydrochlorothiazide, Quinapril hydrochloride
Medicine Name Aciclovir 25 mg/ml Concentrate for Solution for Infusion. Active Ingredients Aciclovir sodium
Medicine Name Aldactone 100mg film coated tablets Active Ingredients Spironolactone
Medicine Name Aldactone 25mg film-coated tablets Active Ingredients Spironolactone
Medicine Name Aldactone 50 mg Film-coated tablets. Active Ingredients Spironolactone
Medicine Name Amlodipine Pfizer 10 mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Amlodipine Pfizer 5 mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Anugesic HC Cream Active Ingredients Balsam Peru, Benzyl Benzoate, Bismuth Oxide, Hydrocortisone Acetate, Pramocaine Hydrochloride, Zinc Oxide
Medicine Name ARICEPT 10 mg film coated tablets Active Ingredients Donepezil Hydrochloride
Medicine Name ARICEPT 5 mg film coated tablets Active Ingredients Donepezil Hydrochloride
Medicine Name Aromasin 25 mg coated tablets Active Ingredients Exemestane
Medicine Name Arthrotec 50 Active Ingredients Diclofenac Sodium, Misoprostol
Medicine Name Arthrotec 75 modified-release tablets Active Ingredients Diclofenac Sodium, Misoprostol
Medicine Name Ativan 1mg Tablets Active Ingredients Lorazepam
Medicine Name ATIVAN INJECTION Active Ingredients Lorazepam
Medicine Name BeneFIX Active Ingredients nonacog alfa
Medicine Name BESPONSA 1 mg powder for concentrate for solution for infusion Active Ingredients Inotuzumab ozogamicin
Medicine Name Bosulif 100 mg, 400 mg & 500 mg film-coated tablets Active Ingredients Bosutinib monohydrate
Medicine Name Cabaser 1mg Tablet Active Ingredients Cabergoline
Medicine Name Cabaser 2mg Tablet Active Ingredients Cabergoline
Medicine Name CAMPTO 20 mg/ml, concentrate for solution for infusion Active Ingredients Irinotecan hydrochloride trihydrate
1 - 0 of 231 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 12 November 2020

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage

Updated on 5 June 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 3 March 2017

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 March 2017 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 4.4 - Alprostadil should be used with caution in patients with cardiovascular and cerebrovascular risk factors

Section 4.8 – addition of  adverse drug reactions myocardial ischaemia and cerebrovascular accident, frequency not known

Updated on 3 March 2017 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 4.4 - Alprostadil should be used with caution in patients with cardiovascular and cerebrovascular risk factors

Section 4.8 – addition of  adverse drug reactions myocardial ischaemia and cerebrovascular accident, frequency not known

Updated on 19 January 2016 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

4.8 – frequency of Erythema updated to Common, duplicate event Hypasthesia deleted, ADRs listed in order of decreasing medical seriousness within each frequency category and MedDRA System Organ Class

10 – date last updated revised

Updated on 19 January 2016 PIL

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

4.8 – frequency of Erythema updated to Common, duplicate event Hypasthesia deleted, ADRs listed in order of decreasing medical seriousness within each frequency category and MedDRA System Organ Class

10 – date last updated revised

Updated on 27 November 2015 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 4.4 – text added regarding the possibility of needle breakage and advising patients not to straighten a bent needle

Section 10 – date last updated revised

Updated on 27 November 2015 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 4.4 – text added regarding the possibility of needle breakage and advising patients not to straighten a bent needle

Section 10 – date last updated revised

Updated on 5 June 2015 PIL

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows

Section 6.5 – updated with a description of the needles

Section 10 – date of revision updated

Updated on 5 June 2015 SPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows

Section 6.5 – updated with a description of the needles

Section 10 – date of revision updated

Updated on 11 December 2014 PIL

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows

Section 4.8 – Reporting of suspected adverse reactions updated from IMB to HPRA

Section 10 – date last revised updated

Updated on 11 December 2014 SPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows

Section 4.8 – Reporting of suspected adverse reactions updated from IMB to HPRA

Section 10 – date last revised updated

Updated on 5 September 2014 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

2 – reworded in line with QRD

4.1 – specifies not indicated for paediatric use

4.3 – typo corrected

4.4 – additional benzyl alcohol text

4.8 – addition of details for reporting suspected adverse reactions

10 – date of revision of text

 

Updated on 5 September 2014 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

2 – reworded in line with QRD

4.1 – specifies not indicated for paediatric use

4.3 – typo corrected

4.4 – additional benzyl alcohol text

4.8 – addition of details for reporting suspected adverse reactions

10 – date of revision of text

 

Updated on 28 August 2014 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Update to sections 2, 4.1, 4.3, 4.4, 4.8 & 10

Updated on 28 August 2014 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to sections 2, 4.1, 4.3, 4.4, 4.8 & 10

Updated on 26 February 2014 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number

Free text change information supplied by the pharmaceutical company

Update to sections 7 & 8

Updated on 26 February 2014 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to sections 7 & 8

Updated on 12 September 2013 PIL

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container

Free text change information supplied by the pharmaceutical company

SPC

Section 6.1 addition of α-Cyclodextrine to list of excipients

Section 6.5 removal of flurocoated rubber stopper and replaced with bromobutyl rubber stopper

Updated on 12 September 2013 SPC

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC

Section 6.1 addition of α-Cyclodextrine to list of excipients

Section 6.5 removal of flurocoated rubber stopper and replaced with bromobutyl rubber stopper

Updated on 27 February 2013 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

2: administrative update in line with QRD template to state excipients with known effect

4.2 – administrative update to cross references

4.3 – rewritten in bullet points in line with QRD template

4.4 – to minimize risk select lowest effective dose, treatment of priapism should be according to local medical practice, use with care in patients who have experienced TIA or other unstable cardiac disorders, not intended for co-administration with other agents for treatment of erectile dysfunction, potential for abuse should be considered in patients with a history of psychiatric disorders or addiction, use with care in patients with heart disease/failure/pulmonary disease – these patients should engage in sexual activity with caution, properly discard device and any unused solution, contains less than 1 mmol sodium (essentially sodium free)

4.5 – effects of combination with other treatments for erectile dysfunction have not been studied,  sympathomimetics may reduce the effect of alprostadil. Alprostadil may enhance the effects of antihypertensives, vasodilative agents, anticoagulants and platelet aggregation inhibitors

4.7 - Alprostadil would not be expected to have an influence on the ability to drive or operate machines

4.8 – rewritten to include a frequency table and text on clinical trial data. Adverse reactions updated in line with latest system organ class definitions and additional events added

4.9 - Overdosage was not observed in clinical trials with alprostadil. If intracavernous overdose of alprostadil occurs, the patient should be placed under medical supervision until any systemic effects have resolved and/or until penile detumescence has occurred. Symptomatic treatment of any systemic symptoms would be appropriate.

6.6 - Caverject is not intended to be mixed or coadministered with any other products (correction to SmPC in line with IMB Schedule).

10 – update to date of revision of text

 

Updated on 27 February 2013 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

2: administrative update in line with QRD template to state excipients with known effect

4.2 – administrative update to cross references

4.3 – rewritten in bullet points in line with QRD template

4.4 – to minimize risk select lowest effective dose, treatment of priapism should be according to local medical practice, use with care in patients who have experienced TIA or other unstable cardiac disorders, not intended for co-administration with other agents for treatment of erectile dysfunction, potential for abuse should be considered in patients with a history of psychiatric disorders or addiction, use with care in patients with heart disease/failure/pulmonary disease – these patients should engage in sexual activity with caution, properly discard device and any unused solution, contains less than 1 mmol sodium (essentially sodium free)

4.5 – effects of combination with other treatments for erectile dysfunction have not been studied,  sympathomimetics may reduce the effect of alprostadil. Alprostadil may enhance the effects of antihypertensives, vasodilative agents, anticoagulants and platelet aggregation inhibitors

4.7 - Alprostadil would not be expected to have an influence on the ability to drive or operate machines

4.8 – rewritten to include a frequency table and text on clinical trial data. Adverse reactions updated in line with latest system organ class definitions and additional events added

4.9 - Overdosage was not observed in clinical trials with alprostadil. If intracavernous overdose of alprostadil occurs, the patient should be placed under medical supervision until any systemic effects have resolved and/or until penile detumescence has occurred. Symptomatic treatment of any systemic symptoms would be appropriate.

6.6 - Caverject is not intended to be mixed or coadministered with any other products (correction to SmPC in line with IMB Schedule).

10 – update to date of revision of text

 

Updated on 30 July 2008 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

update to sections 2 and 6.1 due to change of inactive ingredient

Updated on 30 July 2008 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients

Free text change information supplied by the pharmaceutical company

update to sections 2 and 6.1 due to change of inactive ingredient

Updated on 17 June 2008 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 17 June 2008 PIL

Reasons for updating

  • New SPC for medicines.ie